Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 5mg, 10mg.
BPC-157 is one of the most studied peptides in animal models of injury. The question is what a rat result can, and cannot, say about people.
BPC-157 is a synthetic fifteen-amino-acid peptide described by its developers as a fragment of a protective protein in human gastric juice. It is studied because, in rat models of tendon, muscle and gut injury, it has repeatedly changed the course of healing, with effects on blood-vessel growth and fibroblast movement proposed as mechanisms. The evidence is almost entirely from rodents and cells; human data are limited to three small pilot studies, and no human efficacy trial exists.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 5mg | BC5 | Out of stock | $50 |
| 10mg | BC10 | In stock | $80 |
2 published reports for BPC-157, listed by presentation and batch. Where a batch reference is shown, match it to the batch on the vial label; a report for an earlier batch is historical documentation and does not describe the batch currently supplied. Where no batch reference is published, the report cannot be matched to a vial and is historical documentation only. No report is published for 5mg. Each report describes the sample and the tests shown on it. A purity result does not by itself establish identity, quantity, sterility or endotoxin status unless those tests appear on the report, and a report for one batch does not describe another.
| Presentation | Report | Batch | |
|---|---|---|---|
| 10mg | independent laboratory report | B.3.26 | Open |
| 10mg | independent laboratory report | B.3.26 | Open |
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
In Australia BPC-157 is a Schedule 4 (prescription only) substance under the Poisons Standard, and listed in Appendix D (clause 5), which the states and territories apply through their own poisons legislation to restrict possession without authority; the entries took effect on 1 June 2024 and remain in the June 2026 instrument. It is not an approved medicine in Australia, and no approval elsewhere was identified. BPC-157 is named under S0 (non-approved substances) on the WADA 2026 Prohibited List, prohibited at all times.
Status checked 2026-09-23. Details and sources in the research note.